Our Pipeline

TERN003 Inflammation Molecular Glue Degrader TERN002 Neuroinflammation Molecular Glue Activator TERN001 Inflammation and Fibrosis Molecular Glue Degrader Target Identification Hit Identification Hit Expansion Lead Optimisation IND Enabling Studies

Our focus is to deliver a pipeline of novel, transformative therapeutics to patients suffering from immunological disorders.

90% of TPD Research is undertaken in Oncology.

Significant opportunity to expand to new indications.

ImmunologyOncologyCardio/MetabolicTernaryTx Focus AreasMarket Size (USD, billions)050100150200